Research account from Biocentric’s published case study. Findings are reported for the methods described; limitations are noted below.
Background
This collaborative research investigated the structural and functional characteristics of neuraminidase, an enzyme involved in influenza virus activity.
Research objective
Identify potential inhibitors of neuraminidase using new chemical classes and a multi-target strategy for influenza A and B.
Computational approach
Biocentric reports screening the Ultralight ZINC database with its proprietary in silico tool within a couple of weeks. The multi-target strategy sought compounds predicted to bind neuraminidase proteins from both influenza A and B.
Promising candidates underwent classical molecular dynamics simulations to investigate the stability of their predicted interactions.
Laboratory investigation
The top-selected compounds advanced to in vitro testing in collaboration with the Anti-Viral Drug Discovery Laboratory at the Molecular Biology Institute of the National Academy of Sciences.
Reported findings
The case study reports that one of four leading compounds tested exhibited significant antiviral activity in the laboratory. This is a small selected sample, not a general hit-rate estimate.
The reported compound was structurally distinct from the salicylic acid-based inhibitors discussed in the study, offering a chemical starting point for further investigation.
Interpretation and next steps
The source describes potential for further optimization and development. The public case study does not provide the full assay protocol, concentration-response data, uncertainty estimates or clinical evidence.
Computational affinity and in vitro antiviral activity do not establish safety or efficacy in patients. Further research and experimental validation are necessary.